NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization332.99 mln
Float28.43 mln
Earnings Date05/19/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-78.17
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
DiaMedica Therapeutics is a Minneapolis-based drug development company working to create new treatments for patients with serious conditions affecting blood flow, including stroke, kidney disease, and pregnancy complications. Its primary drug, DM199, is currently being tested in late-stage clinical trials, while a second compound targeting inflammatory conditions remains in earlier stages of research. Founded in 2000, the company is focused on turning its pipeline of experimental therapies into approved medicines that address significant unmet medical needs.
